A CHALLENGING YET ENCOURAGING YEAR OF IMPORTANT ADVANCES
2021 has in many ways been a challenging year, but it has also been a year were Fluicell has taken some of the most important steps forward in the history of the company. In the last CEO Newsletter for 2021, Victoire Viannay looks back on the year that has been, a year that has brought both Fluicell’s entry into regenerative medicine research and development, and an increased market recognition for Biopixlar and microfluidic bioprinting.
The end of the year is not only a time reflect on what has been, but also an opportunity to look forward. We at Fluicell have many exciting things planned for 2022 that we can’t wait to share with you. Not least of these is our upcoming Q1 product release, which will add a second product to our bioprinting product portfolio.
Read all about this and more in the new issue of the Fluicell CEO Newsletter, which you can access here.